Veeva Systems Inc. (VEEV)
| Market Cap | 45.44B -0.2% |
| Revenue (ttm) | 3.46B +16.5% |
| Net Income | 1.01B +25.3% |
| EPS | 6.10 +25.5% |
| Shares Out | 161.91M |
| PE Ratio | 46.01 |
| Forward PE | 29.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,735,951 |
| Open | 276.84 |
| Previous Close | 274.84 |
| Day's Range | 275.91 - 282.81 |
| 52-Week Range | 148.05 - 310.50 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 297.30 (+5.92%) |
| Earnings Date | Aug 26, 2026 |
About VEEV
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides ... [Read more]
Financial Performance
In fiscal year 2026, Veeva Systems's revenue was $3.20 billion, an increase of 16.34% compared to the previous year's $2.75 billion. Earnings were $908.91 million, an increase of 27.27%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for VEEV stock is "Buy." The 12-month stock price target is $297.3, which is an increase of 5.92% from the latest price.
News
New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
Standards-first agent delivers faster and more consistent EDC and DQS builds PLEASANTON, Calif., Sept. 24, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Study Builder Agent, a ...
Veeva rallies after announcing new ‘top 20’ biopharma customer
Veeva (VEEV) announced this morning a new “top 20” biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly, and Regeneron. “With more than 190 live customers and global…
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva
With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top...
Veeva Introduces Falcon Router for Agentic Triage of All Reporting Channels
PLEASANTON, Calif., Sept. 21, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Falcon Router, an industry-specific agent to identify and route potential safety adverse event repor...
Trade Desk announces expanded integrations with Veeva Crossix, IQVIA Digital
The Trade Desk (TTD) announced expanded integrations with healthcare analytics and measurement providers Veeva (VEEV) Crossix and IQVIA (IQV) Digital. The enhancements give pharma advertisers more gra...
Amgen to deploy Veeva Vault CRM globally
Veeva Systems (VEEV) announced that Amgen (AMGN) plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade. “Moving to Vault CRM will help accelerate…
Leading Biotech Selects Veeva Vault CRM Globally
Agentic CRM foundation to help accelerate the delivery of innovative medicines to patients worldwide PLEASANTON, Calif., Sept. 15, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that ...
Veeva Systems Transcript: Citi’s 2026 Global TMT Conference
The discussion highlighted robust growth in commercial and R&D segments, accelerated AI innovation with Falcon and Vault AI, and evolving pricing models focused on business value. CRM migrations and Crossix performance remain strong, while Aspen CRM targets long-term horizontal expansion.
Veeva Systems Transcript: Wells Fargo 21st Annual Healthcare Conference
The event highlighted a strategic focus on building an industry cloud for life sciences, with AI integration (Vault AI and Falcon) driving efficiency and new revenue streams. CRM and data products are seeing strong adoption, and partnerships like IQVIA are unlocking new opportunities.
Veeva price target raised to $330 from $320 at Wells Fargo
Wells Fargo raised the firm’s price target on Veeva (VEEV) to $330 from $320 and keeps an Overweight rating on the shares. The firm says Veeva remains its best idea,…
Veeva to Present at Upcoming Investor Conferences
PLEASANTON, Calif., Sept. 2, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference, Boston,...
Veeva Rises on Sales and Margin Gains, Guidance Raise
Since 2015, Veeva Systems, Inc. (VEEV) shares have received 53 outlier inflow signals and gained over 900%.
Veeva Systems announces Veeva Falcon Safety, agentic safety operation product
Veeva (VEEV) Systems announced Veeva Falcon Safety, an agentic safety operations product to streamline adverse event intake, case processing, and follow-up to reduce costs, increase speed, and maintai...
Veeva Falcon Safety to Work with All E2B-Compliant Safety Systems Across Any Intake Channels
PLEASANTON, Calif., Sept. 1, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Falcon Safety, an agentic safety operations product to streamline adverse event intake, case processi...
Veeva price target raised to $273 from $190 at Citi
Citi raised the firm’s price target on Veeva (VEEV) to $273 from $190 and keeps a Neutral rating on the shares. The firm views the company’s Q2 report as “upbeat.”…
Veeva Systems Stock Is Having Its Best Day Ever as Software Sector Rallies
Veeva Systems stock surges and is having its best day ever after the software company's quarterly earnings and guidance made Wall Street believers.
Veeva price target raised to $305 from $262 at Truist
Truist raised the firm’s price target on Veeva (VEEV) to $305 from $262 and keeps a Buy rating on the shares. The company delivered a strong Q2, exceeding expectations across…
Veeva price target raised to $299 from $272 at JPMorgan
JPMorgan analyst Alexei Gogolev raised the firm’s price target on Veeva (VEEV) to $299 from $272 and keeps an Overweight rating on the shares. The company upped its fiscal 2027…
Veeva price target raised to $283 from $235 at TD Cowen
TD Cowen raised the firm’s price target on Veeva (VEEV) to $283 from $235 and keeps a Buy rating on the shares. The firm said its F2Q beat/raise suggest F1H…
Veeva price target raised to $325 from $275 at RBC Capital
RBC Capital raised the firm’s price target on Veeva (VEEV) to $325 from $275 and keeps an Outperform rating on the shares. The company reported a strong Q2 with revenue…
Veeva price target raised to $330 from $225 at Raymond James
Raymond James raised the firm’s price target on Veeva (VEEV) to $330 from $225 and keeps an Outperform rating on the shares. Veeva delivered another strong Q2 with 19% billings…
Veeva price target raised to $300 from $275 at Stifel
Stifel raised the firm’s price target on Veeva (VEEV) to $300 from $275 and keeps a Buy rating on the shares.